Sign In
Buy INMB
$1.32
-0.1000 (-7.04%)
At Close: Jun 03, 2026
INmune Bio, Inc. Receives Regulatory Approval from UK MHRA to Initiate Phase I Trial of INKmune in Patients with High-risk MDS
01:00pm, Thursday, 11'th Jun 2020
INmune Bio, Inc. (INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announced that t
City of Hope Physicians/Scientists Lead Multiple, Innovative COVID-19 Research Projects
12:00am, Thursday, 21'st May 2020
City of Hope’s physician-scientists and basic scientists are using their expertise to attack the deadly coronavirus on multiple research fronts.
INmune Bio, Inc. (INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announced public
INmune Bio Inc. (INMB) CEO RJ Tesi on Q1 2020 Results - Earnings Call Transcript
02:07am, Friday, 15'th May 2020
INmune Bio, Inc. (NASDAQ:INMB) Q1 2020 Earnings Conference Call May 14, 2020 4:30 P.M. ET Company Participants RJ Tesi - Co-Founder and Chief Executive Officer
INmune Bio, Inc. Announces First Quarter 2020 Results and Provides Business Update
01:00pm, Thursday, 14'th May 2020
LA JOLLA, Calif., May 14, 2020 -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), an immunology company developing treatments that harness the patient’s innate immune system.
INmune Bio, Inc. (INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announced presen
The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight
12:00am, Sunday, 10'th May 2020
The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB)...
INmune Bio, Inc. to Host First Quarter 2020 Earnings Conference Call
08:20pm, Wednesday, 06'th May 2020
INmune Bio, Inc. (INMB), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced that it will host a co
INmune Bio, Inc. to Speak on COVID-19 Therapeutic Panel at Maxim Group’s Infectious Disease Virtual Conference on May 5, 2020
01:00pm, Tuesday, 28'th Apr 2020
INmune Bio, Inc. (INMB), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announced today that RJ Tesi, MD, CEO
Is INmune Bio (NASDAQ:INMB) In A Good Position To Invest In Growth?
12:09pm, Tuesday, 28'th Apr 2020
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Frontiers in Oncology Publishes an Invited Review Highlighting Soluble TNF’s Impact on Breast Cancer
01:00pm, Thursday, 23'rd Apr 2020
INmune Bio, Inc. (INMB) (the “Company”), an immunology company developing treatments that harness the patient’s innate immune system to fight disease, announced publication of an invited review
INMB: Evaluating DN-TNF as COVID-19 Treatment…
02:55pm, Wednesday, 22'nd Apr 2020
By David Bautz, PhD NASDAQ:INMB READ THE FULL INMB RESEARCH REPORT Business Update Testing DN-TNF Platform as Treatment for COVID-19 On April 20, 2020, INmune Bio, Inc. (NASDAQ:INMB) announced that th
INmune Bio Announces Allowance of U.S. Patent Covering Method for Treating Cancer by In Vivo Priming of Natural Killer Cells
01:00pm, Wednesday, 22'nd Apr 2020
INmune Bio, Inc. (INMB), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announced today that the United States
Inmune Bio (INMB) Gets a Buy Rating from Maxim Group
11:30am, Wednesday, 22'nd Apr 2020
Maxim Group analyst Jason McCarthy assigned a Buy rating to Inmune Bio (INMB) today and set a price target of $13.00. The company's shares closed last
Inmune Bio (INMB) Gets a Buy Rating from Maxim Group
11:29am, Wednesday, 22'nd Apr 2020
Maxim Group analyst
Jason McCarthy
assigned a
Buy
rating to Inmune Bio (
INMB
–
Research Report
) today and set a price target of
$13.00
. The company’s shares closed last Tuesday at $4.27.
Accord
